Tempus ECG-AF vs Study Watch
AI Verdict
Choose Tempus ECG-AF if…
Choose Tempus ECG-AF if your primary goal is to proactively identify older patients (65+) at risk of developing new-onset atrial fibrillation within the next year, leveraging existing 12-lead ECG infrastructure. This tool is ideal for integrating into routine cardiology or internal medicine workflows to support earlier risk stratification and targeted follow-up for high-risk individuals.
View Tempus ECG-AF →Choose Study Watch if…
Choose Verily Study Watch if your clinical research study requires continuous, long-term physiological monitoring across multiple parameters like ECG, heart rate, and movement. This prescription-only wearable device is best suited for collecting rich, real-world data for in-depth analysis on a cloud platform, particularly in studies focused on cardiology, neurology, or sleep medicine where sustained data capture is crucial.
View Study Watch →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Tempus ECG-AF | Study Watch |
|---|---|---|
| Pricing | Contact vendor | Unknown |
| Deployment | Software solution, integrated into healthcare facility systems with advanced cardiology algorithms. | The Study Watch is a wrist-worn, multi-sensor wearable device used for data collection in clinical trials. Data from the watch is encrypted and sent securely to the Verily Cloud using a USB syncing and charging cradle and a wireless connectivity bridge (Verily Study Hub). |
| BAA Available | Yes AI-estimated | Unknown |
| FDA Status | Yes AI-estimated | Cleared AI-estimated |
| HIPAA | Yes AI-estimated | Unknown |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
Tempus ECG-AFTempus ECG-AF integrates seamlessly into existing clinical workflows by analyzing readily available 12-lead ECG data, requiring no additional patient interaction or device management by the clinic. In contrast, Verily Study Watch, while designed for patient ease of use, introduces the complexities of device distribution, patient compliance, and continuous data collection management for healthcare providers.
Clinical Value
Tempus ECG-AFTempus ECG-AF offers a clear and immediate clinical value by providing an FDA-cleared, specific risk prediction for developing AF within 12 months, enabling proactive patient management. Verily Study Watch, while collecting rich physiological data and having an irregular pulse monitor, is primarily positioned for clinical research, making its direct, actionable clinical utility for routine care less explicit.
Pricing & Value
Tempus ECG-AFTempus ECG-AF has a transparent and established CMS reimbursement pathway with a specified Medicare rate, which significantly enhances its financial value and ease of adoption for healthcare providers. Verily Study Watch's pricing is not publicly available and lacks a clear reimbursement mechanism, making its financial value proposition less defined for clinical use.
Enterprise Readiness
Tempus ECG-AFTempus ECG-AF is designed for seamless integration into existing healthcare facility systems and is compatible with widely used ECG equipment, demonstrating strong enterprise readiness. While Verily Study Watch is also FDA cleared and HIPAA compliant, the ongoing lawsuit alleging HIPAA breaches, even if denied, could pose a risk for enterprise adoption, and its wearable-plus-cloud model may introduce additional operational complexities.
Innovation
TieBoth tools demonstrate significant innovation in different aspects of healthcare AI. Tempus ECG-AF innovates by leveraging AI for predictive analytics on existing clinical data, providing a novel diagnostic insight. Verily Study Watch showcases innovation in wearable technology, offering continuous, multi-sensor physiological monitoring for comprehensive data collection in clinical research.
Support & Docs
Tempus ECG-AFTempus AI clearly outlines customer support channels, including email and local representatives, and provides resources like FAQs for its products, indicating a structured support system for clinical users. Verily provides user manuals and regulatory documents for the Study Watch, but its general support information appears more geared towards research partners and other products, with less explicit, dedicated customer support for broader clinical deployment of the Study Watch.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Tempus ECG-AF | Study Watch |
|---|---|---|
| Company | Tempus AI, Inc. | Verily Life Sciences |
| Primary Use Case | Analyzes 12-lead ECG recordings to identify patients aged 65 or older at increased risk of developing atrial fibrillation/flutter (AF) within the next 12 months, supporting earlier identification and follow-up. | Non-invasive, continuous physiological monitoring in clinical research, collecting data like ECG, heart rate, and movement for analysis in Verily's cloud platform. |
| Target Population/Setting | Patients 65 years or older without pre-existing AF, pacemakers, ICDs, or recent cardiac surgery. | Clinical research (prescription-only device). |
| Key Data Input/Sensors | 12-lead ECG recordings (analyzed by AI algorithm) | Multiple physiological sensors (ECG, heart rate, electrodermal activity, inertial movements) |
| Categories | Cardiology AI | Cardiology AI, Wearables & Remote Monitoring (RPM) |
| Specialties | Cardiology, Geriatrics, Internal Medicine | Cardiology, Neurology, Sleep Medicine |
Videos
Demos, reviews, and walkthroughs featuring Tempus ECG-AF and Study Watch.